Key Developments: Kissei Pharmaceutical Co Ltd (4547.T)

4547.T on Tokyo Stock Exchange

3,320JPY
23 Jan 2015
Change (% chg)

¥-5 (-0.15%)
Prev Close
¥3,325
Open
¥3,350
Day's High
¥3,350
Day's Low
¥3,295
Volume
78,400
Avg. Vol
98,495
52-wk High
¥3,400
52-wk Low
¥2,150

Search Stocks

Latest Key Developments (Source: Significant Developments)

KISSEI PHARMACEUTICAL CO LTD completes share repurchase
Sunday, 16 Nov 2014 08:00pm EST 

KISSEI PHARMACEUTICAL CO LTD:Repurchased 2,541,700 shares at 7,904,687,000 yen in total on Nov. 17.  Full Article

KISSEI PHARMACEUTICAL CO LTD to repurchase shares
Friday, 14 Nov 2014 02:10am EST 

KISSEI PHARMACEUTICAL CO LTD:Says it will repurchase up to 2,700,000 shares of its common stock, representing a 5.25 pct stake on Nov. 17.Share repurchase price is 3,110 yen per share, the closing price of Nov. 14, or up to 8,397,000,000 yen in total.  Full Article

KISSEI PHARMACEUTICAL CO LTD raises consolidated mid-year outlook for FY 2015
Monday, 27 Oct 2014 03:00am EDT 

KISSEI PHARMACEUTICAL CO LTD:Says the company increased the consolidated mid-year outlook for revenue to 34,610 million yen from 33,800 million yen for FY ending March 2015.Operating profit forecast increased to 5,300 million yen from 4,300 million yen.Ordinary profit forecast increased to 6,430 million yen from 4,800 million yen.Net profit forecast increased to 4,500 million yen from 3,350 million yen.Earnings per share increased to 87.43 yen from 65.09 yen.Comments the gain from revaluation of securities is the main reason for the forecast.  Full Article

KISSEI PHARMACEUTICAL CO LTD announces changes of CEO, chairman and president
Friday, 25 Apr 2014 02:00am EDT 

KISSEI PHARMACEUTICAL CO LTD:Appoints Mutsuo Kanzawa, current president as chairman and Chief Executive Officer.Appoints Masaki Morozumi, current managing director as president to replace Mutsuo Kanzawa.Effective June 27.  Full Article

R&I affirms rating on Kissei Pharmaceutical Co., Ltd. at "A-"
Monday, 10 Feb 2014 01:01am EST 

KISSEI PHARMACEUTICAL CO LTD:Says Rating and Investment Information, Inc. affirmed the rating on Kissei Pharmaceutical Co., Ltd. at "A-".Says rating outlook is stable.  Full Article

KISSEI PHARMACEUTICAL CO LTD raises consolidated full-year forecast for FY 2014
Monday, 23 Dec 2013 07:00pm EST 

KISSEI PHARMACEUTICAL CO LTD:Sees revenue of 68,600 million yen, compared to its previous guidance of 65,500 million yen for the fiscal year ending Mar. 31, 2014.Sees operating profit of 11,400 million yen, compared to its previous guidance of 8,300 million yen.Sees ordinary profit of 12,700 million yen, compared to its previous guidance of 9,600 million yen.Sees net profit of 8,550 million yen, compared to its previous guidance of 6,450 million yen.Sees earning per share of 166.11 yen, compared to its previous guidance of 125.31.Says this is because the company has granted exclusive right of development and marketing of its gout and hyperuricemia treatment to Pfizer Inc.  Full Article

KISSEI PHARMACEUTICAL CO LTD Announces Initiation of Phase I Clinical Trial of KEA-0447/KRP-EPA605 with Subsidiary of Kyorin Holdings Inc
Thursday, 17 Oct 2013 03:00am EDT 

KISSEI PHARMACEUTICAL CO LTD announced that it has initiated a Phase I clinical trial of KEA-0447/KRP-EPA605 which has been promoted under a joint development agreement for the treatment of overactive bladder, with KYORIN Pharmaceutical Co., Ltd., which is a subsidiary of Kyorin Holdings Inc. This drug is a selective prostaglandin EP1 receptor antagonist found in the joint research of KISSEI and Kyorin, and expected to improve urinary frequency by suppressing detrusor overactivity of the bladder.  Full Article

KISSEI PHARMACEUTICAL CO LTD Announces Conclusion of an Agreement about Long-Acting Erythropoiesis Stimulating Agent with JCR Pharmaceuticals Co., Ltd
Monday, 30 Sep 2013 02:00am EDT 

KISSEI PHARMACEUTICAL CO LTD announced that it has signed a collaborative research and development agreement, with JCR Pharmaceuticals Co., Ltd, for a biosimilar to a long-acting erythropoiesis stimulating agent, “darbepoetin alfa”(generic name), which is a treatment of renal anemia.  Full Article

R&I Affirms Rating on Kissei Pharmaceutical Co., Ltd. at "A-"; Rating Outlook Stable
Wednesday, 20 Feb 2013 01:01am EST 

Rating and Investment Information, Inc. announced that it has affirmed the rating on Kissei Pharmaceutical Co., Ltd. at "A-". The rating outlook is stable.  Full Article

Search Stocks